Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics

Dr. Reddy's Laboratories Ltd (RDY)

Today's Latest Price: $65.64 USD

2.38 (-3.50%)

Updated Oct 28 9:46am

Add RDY to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RDY Stock Summary

  • The price/operating cash flow metric for Dr Reddys Laboratories Ltd is higher than only 2.81% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of -41.16%, Dr Reddys Laboratories Ltd's debt growth rate surpasses just 6.79% of about US stocks.
  • Dr Reddys Laboratories Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 211.85%, greater than the shareholder yield of 97.96% of stocks in our set.
  • Stocks that are quantitatively similar to RDY, based on their financial statements, market capitalization, and price volatility, are AGCO, OPK, HSTM, NSSC, and MOG.A.
  • RDY's SEC filings can be seen here. And to visit Dr Reddys Laboratories Ltd's official web site, go to www.drreddys.com.

RDY Stock Price Chart Interactive Chart >

Price chart for RDY

RDY Price/Volume Stats

Current price $65.64 52-week high $73.50
Prev. close $68.02 52-week low $33.33
Day low $65.32 Volume 5,973
Day high $65.83 Avg. volume 201,370
50-day MA $65.25 Dividend yield 0.4%
200-day MA $53.05 Market Cap 10.88B

Dr. Reddy's Laboratories Ltd (RDY) Company Bio

Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.

RDY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$65.64$2249.71 3263%

Below please find a table outlining a discounted cash flow forecast for RDY, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Dr Reddys Laboratories Ltd ranked in the 92th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 3279.5% on a DCF basis. The most interesting components of our discounted cash flow analysis for Dr Reddys Laboratories Ltd ended up being:

  • The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately merely 9.69% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • RDY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 48.7% of tickers in our DCF set.
  • As a business, Dr Reddys Laboratories Ltd experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Dr Reddys Laboratories Ltd? See ANIP, OMI, CYH, SUPN, and ACHC.

RDY Latest News Stream

Event/Time News Detail
Loading, please wait...

RDY Latest Social Stream

Loading social stream, please wait...

View Full RDY Social Stream

Latest RDY News From Around the Web

Below are the latest news stories about Dr Reddys Laboratories Ltd that investors may wish to consider to help them evaluate RDY as an investment opportunity.

Dr. Reddy's launches generic Sensipar in U.S.

Dr. Reddy’s Laboratories (RDY) announces the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Amgen's Sensipar (cinacalcet) Tablets. According to IQVIA Health, the Sensipar had U.S. sales of ~$312M for twelve months ended July 2020. Dr. Reddy’s Cinacalcet Tablets are available in 30, 60, and 90 mg tablets....

Seeking Alpha | October 1, 2020

Dr Reddy's Labs Hits Record High On Settlement Of Patent Litigation

Shares of Dr Reddy's Laboratories soared 10 percent to hit a record high of Rs 5,302.85 after the pharma company informed the settlement of their litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for REVLIM (lenalidomide)

Goodreturns | September 18, 2020

Dr Reddy's Lab shares today hit new highs, extend weekly gains to 20%

Dr Reddy's Laboratories said it has settled a litigation with a unit of Bristol Myers Squibb.Earlier this week, it had reached an agreement to buy Russia covid vaccines

Livemint | September 18, 2020

Dr. Reddy’s launches OTC generic of Pataday in U.S.

Dr. Reddy’s Laboratories (RDY) announces the launch of over-the-counter ((OTC)) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalents of Novartis' Pataday Once and Twice Daily Relief.Dr. Reddy’s Olopatadine Solution is indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander...

Seeking Alpha | September 17, 2020

Top stocks to watch— Dr Reddy's Laboratories, HDFC Bank, TVS Motor, Vedanta, IRCTC, L&T, Bharat Forge, HAL, and more

At 8:00 am, the SGX Nifty was trading 0.07% higher, higher pointing towards a cautious start for Nifty50. Here’s a list of stocks to watch for in trade today.

Business Insider India | September 17, 2020

Read More 'RDY' Stories Here

RDY Price Returns

1-mo -4.88%
3-mo 9.55%
6-mo 30.59%
1-year 66.30%
3-year 86.30%
5-year 4.64%
YTD 62.61%
2019 8.38%
2018 1.18%
2017 -16.47%
2016 -1.67%
2015 -7.76%

RDY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RDY Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8178 seconds.